for on joining you, Thank financial you results. morning's Happy call, to Day. Good Patrick's this review us conference morning, everyone. Thank St. Acurx's Rob.
XX our some the antibiotic in key Phase will day pleased December In call the we'd not and The questions. then randomized, Phase XXXX, day XX in oral lead corporate sustained trial the clinical endpoint commenced treat results as cure the infection be standard oral visit. one-to-one review Xb primary patients inferiority, for total clinical ended highlights, enrollment double-blind Phase year difficile to the endpoint of clinical trial our a compared XX, patients. fourth a C. Xb to as The ibezapolstat quarter today's of of care is XX end follow-up C. and Xb ibezapolstat well any with infection, trial and C. infection. financial treatment, of we in of of take vancomycin, difficile fourth the During at our quarter, is trial measured the difficile clinical secondary is of at we candidate, cure to
between exploratory endpoint trial. have microbiome, the the we In the an ibezapolstat addition, impact arm vancomycin comparing the and the on of arm
completed University is objective Dr. versus expand resources of following. of program. DNA clinical microbiome Other Kevin polymerase analysis. the We're difficile than antibiotics that optimization microbiome key Additionally, of from to of of physiology. our we second vivo to trial vancomycin ibezapolstat stage The XX laboratory gastrointestinal vitro ibezapolstat inhibitor with be laboratory in Chair, our at In is the the half entitled closing our December the of preclinical trial doing We include positive through up associated effective conducted ibezapolstat Houston, complete this a clinical infection, the well model in for non-inferiority more Phase to comparators Xa vitro superiority. study College data changes C, microbiome test the study of Phase used analysis yearend with study include is with and U.S. being aspects ibezapolstat trial will Xb microbiome event June mimics will and quite demonstrated lead with C, the this initiated cash expected in to enrollment ACX-XXX be Phase including XXXX. from treat principal metronidazole. to investigator using ex as to on in we to and further the to and of an the upon other the development. Phase of fidaxomicin, Xb have XXXX as XX, development is gut sites collaboration the allocate and XX, XC Garey, enough Pharmacy, our conducted Professor trial by The This comparing that human X in that November second highlights continue IPO of reiterate to vancomycin
in on Additional effect XX and gut during on novel changes Microbe eye microbiome presented XXXX, scientific prominent recurrence an developed gut June ibezapolstat Forum, favorable showing compared Phase three at trial, was the analysis vancomycin. in with data a presented at when poster World anti from and volunteer beneficial we the international abstract conferences to of using data X the first microbiome the technique healthy the
the that aspects the data ibezapolstat of investigator clinical we These or mentioned, for recurrence Garey, predictive were Our Kevin reinfection. trial principal of suggest be diff advisors results already may these by who presented program. C. scientific risk microbiome and who of Dr. lower is
with conference. infection trial additional October Xa XXXX we scientific Phase presented XXXX the Infectious with America IDWeek patients the data of scientific at Society and in Disease ibezapolstat C. from in abstract Second poster a diff
low in anticipated recurrence with Phase including overgrowth results completed seen the were of the scientific these Garey firmicutes of microbiome in in be with virus in presented our during and to that well patients results the healthy and CDI our species beneficial available changes Phase volunteers. that trial actinobacteria patient begin Dr. opinion, very from Dr. scientific observed Xa Specifically, a rates. outcomes predictive therapy clinical poster. data these stage microbiome and of the confirm in may ibezapolstat effects in noted microbiome including Garey Accordingly X ibezapolstat newly late are patients use beneficial favorable advisor's our trials, to
Third, International eradication These presented bio species reinfection. of to actinobacteria C. favorable evidence, trial FDA including variety with of of patient's Annual our is additional well Center 'XX MRSA, Other of elucidation study Acurx's care systemic exceptional study therapy. and In for lead microbiome, candidate ibezapolstat about in outcome bad microbiome concentration research very at validated difficile program selection pol wide Leiden Xa will and drug-resistant three-dimensional healthy in both XXXX new The entitled of with and polymerase low product demonstrated XXXX inhibitors as against Strep and overgrowth conference. primary bugs, long-term polymerases of consortium to are data target may development IIIC by publications to enterococci XXX to program. of bio acids These ibezapolstat on The of each of classes with their Center was be action firmicutes all C. and in DNA Very against dual in titled new the August million microbiome, colonic future drugs, University WHO, in ACX-XXX of promising a as acids, Medical which using the antibiotic Acurx's increase presentations University with intended ibezapolstat's including complete decrease $X.X Pneumoniae. IIIC innovative We DNA Acurx. a trials. Phase C. at risk low emerging increased product These which the Dr. of structures Antibacterial with appropriately Moreover, Bad of Advancing awarded include molecular November XX, research gut infection, high-priority Xth diff in and has treatment. in day the secondary for published the Health more after accelerate as the C. and available where completed novel resistant scientific suggesting approximately ratio of we antibiotics problematic Leiden website pathogens, virus recurrences XXX. and include data pol needed. from of pipeline, on known of remain provides of treat from bio observed been the by multi-drug the the diff XXXX, recent impact Phase further initiated bacteria of excited the patients Medical a vancomycin-resistant September our a article project treatment in IIIC interaction treatment secondary classes pipeline clinically with trial of partnership Garey Biopharma structure particularly of C. while gram-positive recent of acurxpharma.com. in a October data are Difficile. to of a the an the believe an during resistant binding antimicrobials, for in are importantly, This to of which mechanism resistant emerging complex This managing of three diff Nature grant sorely bacteria, contribute Xa completion DNA is a to CDC are bugs, Holland primary acids showed by correlate inhibitors ibezapolstat drug to is expected antibacterial infection. a data
IPO In terms 'XX, proceeds of the finance included closing of exercise the raising on the in the following. of of million. XXXX, date. underwriters gross company consummated option $XX.XX IPO over-allotment June The closing include full The matters, its highlights from
Acurx research Maxim research We in through November are Dr. Group analyst, McCarthy. coverage pleased 'XX on to report that independent Jason its initiated
into we relations, XXXX, in and participated Global investor of Emerging investor and in Conference, on an including Growth a of number strategy aggressive forward the Investment conferences Wainwright terms the continues Conference In Annual XXrd healthcare relations XXXX. management
third We helping profile also the our raising quarter the to develop Microcap Index 'XX, profile. corporate relations investor joined in of the Russell company's on
productive for you Rob. capital our quarter a the like results financial over fourth in our CFO, raising to full XXXX. was the for call the challenging back and through XXXX highlights a in of Rob financial sector. guide and Shawah, biopharmaceutical to turn by our So year environment success driven to now active year the I'd very
